⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial

Heikki Joensuu Eva Wardelmann Mikael Eriksson Annette Reichardt Kirsten Sundby Hall Jochen Schütte Silke Cameron Peter Hohenberger Harri Sihto Philipp J. Jost Lars H. Lindner Sebastian Bauer Bengt Nilsson Raija Kallio Tommi Pesonen Peter Reichardt

View at Publisher

Ask AI

Bookmark

Share

Abstract

Kaplan-Meier estimates of recurrence-free survival of patients with KIT exon 11 substitution mutation (A) and patients with KIT exon 9 mutation (B). The 5-year and 10-year survival rates are shown. Censored patients are indicated with a bar

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Joensuu et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523b20 https://doi.org/10.1158/1078-0432.27030691.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial2024
2Supplementary Figure S3 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial2024
3Supplementary Figure S3 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial2024
4Supplementary Figure S1 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial2024
5Supplementary Figure S1 from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial2024

Data from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial2024
Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024
Supplementary Figure S4 from Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Imatinib and Adjuvant Therapy Era2024